This trial will see if a new drug, GSK3511294, is non-inferior to current treatments for severe asthma with an eosinophilic phenotype. All participants will continue their standard of care asthma treatment.
1 Primary · 3 Secondary · Reporting Duration: Baseline (Day 1) and up to Week 52
1700 Total Participants · 2 Treatment Groups
Primary Treatment: GSK3511294 (Depemokimab) · Has Placebo Group · Phase 3
Age Any Age · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|GSK Investigational Site||100.0%|
|Did not meet criteria||75.0%|